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Rheumatoid arthritis
AbstrAct
it is believed that therapy for rheumatoid arthritis (RA) is 
the most effective and beneficial within a short time frame 
around RA diagnosis. This insight has caused a shift from 
research in patients with established RA to patients at 
risk of developing RA and recently diagnosed patients. it 
is important for improvement of RA therapy to understand 
when and what changes occur in patients developing 
RA. This is true for both seropositive and seronegative 
patients. Activation of the immune system as presented 
by autoantibodies, increased cytokine and chemokine 
production, and alterations within several immune cells 
occur during RA development. in this review we describe 
RA pathogenesis with a focus on knowledge obtained from 
patients with arthralgia, pre-RA and recently diagnosed 
RA. Connections are proposed between altered immune 
cells, cytokines and chemokines, and events like synovial 
hyperplasia, pain and bone damage.
InTroduCTIon
Rheumatoid arthritis (RA) is a systemic inflam-
matory autoimmune disease characterised by 
inflamed joints and bone damage. As with any 
disease RA has a series of events leading up 
to its diagnosis. There are six phases that a 
patient can experience throughout the devel-
opment of RA. These phases are ‘genetic 
risk factors’, ‘environmental risk factors’, 
‘systemic autoimmunity’, ‘symptoms without 
arthritis’, ‘undifferentiated arthritis’ and 
‘RA’.1 Pre-RA patients are patients who are at 
risk for developing RA and who in the future 
will be diagnosed with RA when multiple 
criteria are met.2 Pre-RA patients can have 
autoantibodies such as anticitrullinated 
protein antibodies (ACPA) or rheumatoid 
factor (RF) but can also remain seronegative 
for these autoantibodies. Within the time 
frame of being a patient with arthralgia and 
receiving RA as diagnosis, multiple processes 
can take place causing autoimmunity, pain 
and bone erosions. Full comprehension of 
how RA develops over time is of importance. 
By understanding this, therapies can be devel-
oped to prevent RA instead of treating symp-
toms. In this review we describe RA pathogen-
esis with a focus on knowledge obtained from 
patients with arthralgia, pre-RA and recently 
diagnosed RA. We describe the pathogen-
esis for seropositive as well as seronegative 
patients. The complex interactions that 
compose inflammation are subdivided in the 
next sections and describe serum markers 
such as cytokines and chemokines, inflamma-
tory cells and local changes in the synovium. 
Connections are proposed between altered 
immune cells, cytokines and chemokines, 
and events like synovial hyperplasia, pain and 
bone damage. 
Cytokines and chemokines from arthralgia to rA
Activation of the immune system during RA 
development can be monitored via measuring 
proteins within the blood, such as cytokines 
and chemokines. As blood is easily accessible, 
it represents a medium that might be ideal for 
diagnosis and monitoring disease progress.
Already prior to the development of auto-
antibody positivity changes in cytokine and 
chemokine levels have been observed within 
blood. Cytokines preceding CCP positivity in 
pre-RA patients are interleukin (IL)-1alpha, 
IL-6 and IP-10.3 The proportion of pre-RA 
patients positive for these cytokines was 
Key messages
 ► Seropositive (arthralgia) patients display an array 
of altered cytokines and chemokines especially 
compared with seronegative (arthralgia) patients.
 ► There is a knowledge gap concerning mechanisms 
of seronegative rheumatoid arthritis (RA) 
development.
 ► RA is a dynamic disease in its development, which 
is best studied in large longitudinal cohorts.
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higher compared with controls. The first significantly 
elevated count of cytokines and chemokines was found 
about 7.2 years prior to receiving RA as diagnosis. A rela-
tionship was found between the number of elevated cyto-
kines and chemokines and time of diagnosis, with higher 
counts being associated with a shorter time remaining to 
diagnosis.3 This increase in number of elevated cytokines 
has also been reported by others where a rise of cytokines 
was observed from 2 to 3 years prior to RA diagnosis inde-
pendent of the presence or absence of CCP.4
Insight into which cytokines and chemokines play a 
role in the development of RA is of interest to under-
stand RA pathogenesis. Altered cytokine and chemo-
kine levels were found in patients with arthralgia. IL-17A 
for example was increased in patients with seropositive 
arthralgia compared with healthy controls.5 Additionally 
IL-5 is an elevated cytokine in pre-RA patients positive 
for RF compared with controls. IL-5 is also elevated in 
pre-RA patients compared with patients with seropos-
itive arthralgia not receiving RA as diagnosis.5 6 This 
indicates that IL-5 and IL-17A play a role in RA devel-
opment. However, IL-17A and IL-5 were not found to 
be significantly altered in seronegative patients. More 
importantly the significance of cytokine and chemokine 
levels was found to be influenced by the presence of 
autoantibodies. Indeed stratification for autoantibodies 
reveals major differences between seropositive and sero-
negative (pre-)RA patients. After stratification for RF the 
only significantly dysregulated cytokines were IL-8 and 
IL-13 in RF-negative pre-RA patients.5 In seropositive 
(pre-)RA patients multiple cytokines and chemokines are 
differentially expressed compared with healthy controls. 
For patients with RF-positive arthralgia compared with 
controls, IL-2RA, IL-5, IL-9, IL-13, IL-17 and MIG became 
significantly different after stratification for RF positivity.5 
This could indicate different processes underlying the 
development of RA in seronegative patients compared 
with seropositive patients.
In seronegative patients with RA, IL-10 was increased 
while eotaxin and Rantes were decreased compared with 
healthy controls.6 Overlap in differential expression 
compared with controls between patients with seroposi-
tive arthralgia and patients with seropositive RA consists 
of IL-1beta, IL-2, IL-1RA, IL-17, IL-4, IL-15 and IL-2R.6 
Other cytokines and chemokines that become signifi-
cantly different after RA diagnosis are tumour necrosis 
factor (TNF)α, interferon (IFN)α, MCP-1 and MIP-1α.6
Overall, the cytokine and chemokine data do confirm 
activation of the immune system prior to RA diagnosis. 
Nonetheless, it is difficult to determine the exact source 
of the detected cytokines and chemokines within blood 
as multiple cells can secrete the same cytokine or chemo-
kine. In addition, the consequences of some elevated 
cytokines are difficult to interpret due to simultaneous 
increase of their antagonists such as IL-1R and IL-2R 
for, respectively, IL-1 and IL-2. An interesting effect of 
elevated cytokines and inflammation-related factors such 
as prostaglandin E2 is their ability to increase nociceptor 
neuron sensitivity, resulting in pain signalling.7 Both 
seropositive and seronegative patients with arthralgia 
experience pain. The limited data so far suggest that 
less cytokines are differentially expressed within sero-
negative pre-RA patients compared with the differential 
expression in seropositive pre-RA patients. This raises 
the question whether the elevation of IL-8 is enough to 
explain the pain complaints in patients with seronegative 
arthralgia or whether a more elaborate inflammation 
such as seen in seropositive patients is needed to result in 
inflammation-induced pain.
Individual levels of cytokines and chemokines might rise 
over time within a single patient. These increases in cyto-
kine and chemokine levels over time during RA develop-
ment need to be further examined in follow-up studies as 
most of the current data are derived from cross-sectional 
studies. Additionally, future studies should broaden or 
extend the array of cytokines and chemokines measured 
and correct them for autoantibody presence. The studies 
should preferably take patients with both seropositive and 
seronegative arthralgia and follow these patients to deter-
mine time to RA diagnosis. These studies can elucidate 
which cytokines and chemokines are altered at which time 
point during RA development and just after RA diagnosis. 
TNFα for example is a cytokine that is altered after RA 
diagnosis. The knowledge that TNFα so far has not been 
reported differently prior to RA diagnosis is of interest 
when it concerns treatment. Inhibition of TNFα already 
occurs in daily practice in patients with diagnosed RA. It 
would be interesting to know whether inhibition of TNFα 
in patients with arthralgia would influence their chance on 
developing RA by inhibiting a rise of TNFα levels. Future 
studies should therefore also focus on the effectiveness of 
treatment prior to RA diagnosis.
Immune cells in the development of rA
Immune cells play an important role in the development 
of RA. Multiple cell types can become involved at different 
time points during RA development and progression. In 
the next section different types of immune cells that have 
been examined in the blood of patients with arthralgia 
or RA will be discussed. Possible links between cell types 
or above-reported cytokines and chemokines and their 
effects will be described (see figure 1).
Patients with arthralgia
Studies reporting on changes within immune cells at the 
arthralgia phase are limited. The information available on 
immune cells is somewhat contradictive and only focused 
on patients with seropositive arthralgia (see table 1). Two 
studies from the same group showed the lack of differences 
on absolute numbers of naïve T cells, T central memory 
cells, effector memory and terminal differentiated effector 
memory T cells, as well as CD19+ B cells, compared with 
healthy controls.8 9 These studies were based on cross-sec-
tional comparisons of patients with seropositive arthralgia 
with healthy controls. A limitation of these studies is that 
it is not reported whether these patients with seropositive 
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arthralgia developed arthritis or RA, leaving open the 
question whether the lack of difference is due to non-con-
vertment of these patients with seropositive arthralgia into 
patients with RA. Some studies did report on patients with 
arthralgia who converted to patients with the diagnosis of 
RA.
Regulatory T cells
CD4+CD25+FoxP3+ T cells (Tregs) can suppress other 
immune cells by regulating their proliferation and 
cytokine production. In a study on patients with sero-
positive arthralgia, no differences were detected in the 
percentage and number of naïve CD4+CD25+FoxP3+ 
T cells compared with healthy controls.10 The same 
was found for activated CD4+CD25+FoxP3+ T cells. 
Comparing the CD4+CD25+FoxP3+ T cells from patients 
with seropositive arthralgia who converted to patients 
with RA with those who did not resulted again in no 
detectable differences. These results indicate that Tregs 
are not altered on the level of numbers and frequencies 
Figure 1 Schematic overview of different immune processes in blood during the development of RA. Upper left: CD56dim NK 
cells are capable of killing autoimmune cells like B cells and CD8 T cells. RF immune complexes bind to the FcγRIIIa receptor 
on NK cells causing apoptosis and thereby reduce CD56dim NK cell number. Cytokines like IL-5 exert their influence on B cells 
resulting in more immunoglobulin secretion. MIG attracts CD8 T cells via the CXCR3 receptor to lymph nodes where these cells 
become short-lived effector cells. B cells migrate out of the bloodstream. IL-13 prevents synovial fibroblasts from apoptosis 
induced by NO. Synovial hyperplasia will develop. Upper right: Levels of autoantibodies have risen, epitope spreading has 
occurred, and antibody modifications like glycosylation, sialylation and galactosylation are altered. CD56dim NK cell number 
is still reduced and start to dysfunction by lowered IFNγ production. Reduction of IFNγ results in skewing towards Th17 cell 
differentiation. Th17 cells and Th17 subpopulations migrate from blood under the influence of MIG, MIP-1α and MCP-1. 
Neutrophils are activated and recruited from blood via MIP-1α. Lower left: The cytokines IL-8 and IL-13 are altered in the blood 
of patients with seronegative arthralgia. IL-8 could induce pain by binding to receptors on nociceptor sensory neurons. IL-13 
prevents synovial fibroblasts from apoptosis induced by NO. Synovial hyperplasia will develop. Lower right: Increased IL-10 
and decreased Rantes and eotaxin are detected. CD56bright NK cell number is increased. These cells are capable of secreting 
proinflammatory cytokines like IL-13. Any type of arrow displayed within the figure are suggested links between antibodies, 
immune cells and cytokines or chemokines. The indicated cytokines and chemokines are not necessarily secreted by the 
depicted immune cells. IFNγ, interferon gamma; IL, interleukin; RA, rheumatoid arthritis; RF, rheumatoid factor.
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within the blood of patients with arthralgia. Whether 
Tregs are functionally different in patients with 
arthralgia is still unknown.
CD8+ T cells
A study comparing patients with seropositive arthralgia 
who converted to patients with RA with non-converters 
showed decreased CD8+ cytotoxic T cells approximately 
24 months prior to arthritis development.11 The CD8+ 
cytotoxic T cells described in the article are determined 
by CD3 and CD8 positivity and represent a rather diverse 
group. Not all CD8+ T cells have the same ability to be 
cytotoxic. Additionally there is a description of CD8+ 
T cells to be suppressive or regulatory. These cells are 
characterised by the production of IL-10 and TGFβ. The 
effects of reduced CD3+CD8+ T cells in patients with 
arthralgia need to be further investigated with focus on 
specific subsets and their function. Of interest would also 
be whether these cells migrate to other sites of the body. 
The migration and longevity of CD8+ T cells could be 
influenced by chemokines like MIG, which binds to the 
receptor CXCR3. As described in the previous section 
about cytokines and chemokines, patients with RF sero-
positive arthralgia have elevated levels of MIG. Signalling 
via CXCR3 receptor leads to the accumulation of CD8+ T 
cells in the marginal zone where these cells differentiate 
into short-lived effector cells.12 An alternative reason for 
decreased CD8+ T cells could be the elimination of auto-
reactive CD8+ T cells by other immune cells.
CD56dim NK cells
The suggested explanation of CD3+CD8+ T cells elimi-
nation by other immune cells could be due to NK cells. 
NK cells have been shown to exhibit cytotoxic abilities, 
especially the CD56dim NK cells. NK cells could influence 
autoimmune cells via direct lysis or indirectly via targeting 
DCs. A single study reported less NK cells in patients with 
seropositive arthralgia compared with controls.8 More 
importantly CD56dim NK cells were decreased, not the 
CD56bright NK cells. The decrease in CD56dim NK cells is 
likely the consequence of apoptosis induced by binding 
of RF to the FcγRIIIa. Apoptosis was in vitro further 
induced when IL-2 was added. As described above IL-2 
is increased in the blood of patients with seropositive 
arthralgia. The reduction of CD56dim NK cells was meas-
ured in patients with seropositive arthralgia of which it is 
not described whether they developed arthritis. There-
fore it is only guessing when these changes in NK cells 
occur during RA development. The reduction in NK 
cells is likely to occur at a later phase if these CD56dim NK 
cells are responsible for the decrease in CD3+CD8+T cells 
within patients with arthralgia. The reduction of CD56dim 
NK cells could also impact the presence of other (autoim-
mune) cells such as Th17 cells and B cells.
Th17 cells and Th17 cell subpopulations
A single study has investigated Th17 cells in patients with 
arthralgia. CD4+CD161+ cells are known for their ability 
to differentiate into IL-17-producing cells. Additionally 
CD4+CD161+ cells include IL-17+IFNγ+ double positive 
cells and the non-classical Th1 cells. In patients with 
arthralgia higher percentage and absolute number of 
CD4+CD161+ cells were reported compared with healthy 
controls. Additionally the IL-17+IFNγ+ double positive 
cells were reported to be increased in patients with sero-
positive arthralgia versus healthy controls.9 Unfortunately 
it was not reported whether the patients with seropositive 
arthralgia within the study developed RA. It therefore 
remains a question whether the differences found is due 
to RA development or whether it is a common finding in 
patients with arthralgia. Direct data on Th17 cells within 
the arthralgia phase are still missing, although these indi-
rect results on CD4+CD161+ cells give a first indication of 
a possible increase in Th17 cells in patients with seropos-
itive arthralgia.
B cells
B cells can differentiate into plasma cells, producing anti-
bodies that will bind to antigens and activate the immune 
system. Approximately 10 years prior to RA diagnosis, 
autoantibodies can be detected in individuals.13 Exam-
ples of autoantibodies are RF, ACPA and antibodies 
against carbamylated antigens (anti-CarP). Even though 
these antibodies are described as autoantibodies, no clin-
ical disease is detected shortly after the first appearance 
of these antibodies. This observation questions whether 
these autoantibodies are as pathogenic as they have 
been described. The pathogenicity might depend on the 
glycosylation states of autoantibodies.14 15 The number 
of CD27+ memory B cells is decreased in patients with 
seropositive arthralgia who converted to patients with 
RA compared with non-converters.11 This decrease was 
reported in patients with arthralgia who developed RA 
within 12 months but not in those who converted at a 
later time point.
The start of epitope spreading of autoantibody 
responses is reported approximately 2–3 years prior to 
RA diagnosis.4 Along this time frame changes within 
bones also occur. During the development of RA cortical 
bone thickness but not trabecular bone decreases in 
patients with ACPAs.16 Cortical fenestrations are addi-
tionally more abundant in ACPA-positive participants. 
Although reduction of bone mineral density occurs at 
an early stage, only at time of diagnosis the changes are 
such that they differ from other non-inflammatory joint 
diseases like osteoarthritis.17 It is a question whether the 
early changes in bone mineral density as seen in patients 
with arthralgia already contribute to the induction of 
pain. Recently certain types of ACPA have been described 
to induce osteoclastogenesis. A subset of ACPAs that are 
reactive to enolase and vimentin can induce osteoclasto-
genesis and osteoclast activation.18 19 IL-8 can be secreted 
by osteoclasts, which can subsequently result in pain 
via binding to the IL-8 receptor on nociceptor sensory 
neurons.20
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The ACPA against vimentin was shown to be sialylated. 
This is interesting in the context that the percentage 
of glycosylation as well as sialylation of total IgG1 and 
total ACPAs was reduced in asymptomatic ACPA-positive 
patients who were diagnosed with RA within 12 months 
compared with those who were not diagnosed with RA 
within 12 months.14 Additionally, galactosylation of total 
ACPAs was decreased 3 months prior to RA diagnosis.15 
Data on the sequential order of events about appearance, 
modifications such as glycosylation, sialylation and galac-
tosylation, and concentration of these possible patho-
genic subsets of ACPAs and bone erosions within the 
same patients at the same time are lacking. The impor-
tance of these ACPAs and whether they indeed induce 
bone erosion in humans need further investigation.
Patients with RA
In comparison with patients with arthralgia, more is 
known about immune cells in patients with RA. The 
immune cells described below are derived from the blood 
of patients with RA (see figure 1 and table 2).
Invariant NK T cells
A single study investigated invariant NK T cells within 
patients with recently diagnosed RA and found a 
reduced frequency of invariant NK T cells.21 Interest-
ingly these cells from patients with RA proliferated less 
when exposed to alpha-galactosylceramide. This reveals 
that invariant NK T cells from patients with RA are not 
only decreased in frequency but also harbour functional 
changes. Whether invariant NK T cells play a pathogenic 
role in RA is still unclear. Decreased invariant NK T cells 
are also found in osteoarthritis, indicating that a decrease 
in these cells is not specific for RA.21
NK cells
In agreement with findings in patients with arthralgia, 
NK cells were decreased in patients with RA compared 
with healthy controls.8 Different subtypes of NK cells 
were affected in patients with seropositive RA compared 
with patients with seronegative RA. In patients with 
seropositive RA, the CD56dim NK cells were decreased 
compared with healthy controls. Additionally the NK 
cells from patients with seropositive RA produce less IFNγ 
compared with healthy controls. This difference in IFNγ 
production was not observed in patients with seroposi-
tive arthralgia. The reduced IFNγ production by NK cells 
could lead to an increase in cells differentiating to Th17 
cells.22 For patients with seronegative RA, the CD56bright 
NK cells were found to be increased compared with 
healthy controls. CD56bright NK cells are producers of 
multiple cytokines and dependent on the stimulation can 
secrete IL-10 and IL-13.23 These cytokines, as discussed 
before, are dysregulated in seronegative (arthralgia) 
patients.
Neutrophils
Neutrophils are recruited from the blood by chemokines 
like IL-8 and MIP-1α and are numerous in RA synovial 
fluid. Neutrophils from patients with RA are functionally 
different from healthy controls. They display a more acti-
vated status and are primed to produce reactive oxygen 
species.24 Additionally neutrophils from patients with RA 
form more often neutrophil extracellular traps (NETosis) 
compared with neutrophils from healthy controls.25 
Furthermore, neutrophils of patients with RA have an 
expanded life span. Most of the described features can 
be explained by the inflammatory environment in which 
RA neutrophils reside. IL-8 for example is, besides a 
neutrophil attractant, also a factor that delays neutro-
phil apoptosis. TNFα is another antiapoptotic cytokine 
for neutrophils. TNFα as well as IL-17 are capable in 
promoting NETosis.25 Interestingly normal neutro-
phils needed TNFα priming before IL-17A can induce 
NETosis. TNFα levels are however reported to be altered 
in patients with RA but not in patients with arthralgia. 
This raises the question whether the rise of TNFα levels 
is accompanied by increased NETosis, and if not whether 
the rise in RF and ACPA levels or specific modifications 
of these antibodies is enough to induce NETosis. The 
NETosis could then result in epitope spreading of anti-
body responses due to exposed citrullinated proteins on 
NETs. Binding of autoantibodies to exposed citrullinated 
proteins could then lead to an escalation of inflammation 
and subsequently secretion of additional cytokines like 
TNFα. Neutrophils are, besides a source of autoantigens, 
capable of secreting matrix metalloproteinases (MMPs) 
such as MMP-8 and MMP-9. These MMPs cause degra-
dation of collagens within the extracellular matrix and 
activation of IL-1 beta. The NETs from neutrophils can 
additionally activate synovial fibroblasts.25 Synovial fibro-
blasts are a source for, for example, MMP-1 and MMP-3. 
The cocktail of MMPs causes tissue damage. Neutrophils 
are thus multifactorial contributors to RA pathology.
Th17 cells and Th17 cell subpopulations
In patients with recently diagnosed RA, the role of Th17 
cells has been more extensively examined than in patients 
with arthralgia. Th17 cells are a heterogeneous group 
composed, among others, of non-classical Th1 or Th17.1 
cells.26 Th17 cells are increased in the peripheral blood 
of patients with RA compared with healthy controls.27–30 
This increase was associated with increased disease 
activity as measured by DAS28 and CRP.27 CD4+CD161+ 
T cells were decreased in numbers in patients with RA 
compared with healthy controls and patients with sero-
positive arthralgia.9 Within these CD4+CD161+ cells, Th17 
cells were increased in patients with RA compared with 
controls, while non-classical Th1 cells were decreased 
in patients with newly diagnosed RA compared with 
patients with seropositive arthralgia. The increase of 
CD4+IL-17+ cells was confirmed by others within blood 
but not lymph nodes of patients with early RA compared 
with at risk individuals and healthy controls.31 Remark-
ably there is a possible time dependency of Th17 cells 
involvement for patients with ACPA-negative RA. This 
is based on the observation that more Th17 cells are 
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correlated with a shorter disease duration,32 while for 
ACPA-positive patients this correlation does not hold and 
might account for the possibility to distinguish ACPA-pos-
itive patients from ACPA-negativepatients based on their 
increased levels of Th17 cells.
The importance of Th17 cells after the development 
of RA is still a matter of debate. Within patients with 
early RA, Th17 cells, IL-17+IFNγ+ double producers and 
CD4+CCR4+CCR6+ T cells were increased in synovial fluid 
compared with paired blood samples.27 However at late-
stage RA the percentage of IL-17 producing cells within 
CD4+CD161+ cells was found to be higher in blood than 
in synovial fluid.9 IFNγ and IL-17 double producers were 
similar, while non-classical Th1 cells were found to be 
increased in synovial fluid compared with blood. These 
observations lead to the question whether Th17 cells 
within patients with RA remain Th17 cells that migrate 
to the joints. Th17 cells could also change characteristics 
at sites of local inflammation such as the joints. Another 
possibility is the specific attraction of Th17 cell subpop-
ulations to the joints. In addition to MIG, MIP-1α and 
MCP-1 become altered in the blood of patients with RA. 
MIP-1α and MCP-1 are both able to induce migration of 
cells that express the CCR4 receptor. The combination of 
MIG, which signals via CXCR3, with MIP-1α and MCP-1 
could be the mix of attractants to induce migration of 
Th17, CCR4+CXCR3+DP cells and non-classical Th1 cells 
from blood towards the joints.
The IL-17 produced by Th17 cells and Th17 cell 
subpopulations contributes to RA pathogenesis by acti-
vating other immune cells like macrophages but also 
synovial fibroblasts. The activation of these cells leads 
to the expression of receptor activator of nuclear factor 
kappa-B ligand (RANKL) that can induce osteoclas-
togenesis via binding to receptor activator of nuclear 
factor kappa-B (RANK) on osteoclast precursors. These 
osteoclast precursors then differentiate into osteo-
clasts. Additionally cytokines like IL-1 can bind to the 
IL-1 receptor on osteoclasts and activate them.33 The 
combined actions of Th17 cells, Th17 cell subpopula-
tions, macrophages, neutrophils and synovial fibroblasts 
and their secreted proinflammatory cytokines are likely 
the cause of changes in bone mineral density detected 
in, for example, hands of patients with recently diag-
nosed RA.34–37
B cells
Similar to what is found in patients with arthralgia, 
conventional memory CD27+ B cells were lower in patients 
with RA compared with healthy controls. Additionally 
activated CD80+ B cells were found to be decreased in 
patients with RA.11 Autoantibody production occurs 
throughout the development as well as the progression 
phase of RA. The functionality of B cells from patients 
with RA is likely not different compared with B cells from 
patients with arthralgia. The function of B cells besides 
the production of antibodies should be further exam-
ined. Possible research directions of future studies are 
the function of B cells as antigen-presenting cells and the 
function of B cell-derived cytokines.38
Synovial inflammation in the development of rA
Synovial biopsies from patients with systemic autoim-
munity (ACPA-positive or RF-positive) at risk of RA 
showed minimal infiltration by T cells but absence of clear 
synovial inflammation. No markers for infiltrating cells 
were found to explain arthritis development. CD3+CD8+ 
T cells however showed a trend for an association with 
arthritis development, although this trend was found in 
uninvolved joints in individuals developing arthritis.39 
Absence of cellular infiltration has also been reported in 
newly diagnosed treatment-naïve patients with RA, where 
only 4 out of 15 patients showed clear immune cell infil-
tration in their biopsies.9 In the case of clear immune 
cell infiltration mostly B cells, T cells and macrophages 
are found.40 The influx of immune cells in the synovium 
of patients with early RA with a disease duration of less 
than 1 year did not differ in the type of cellular influx 
compared with the synovium of patients with RA with a 
duration of more than 5 years.41 Because of the heter-
ogeneity between the reports showing either presence 
or absence of immune cell infiltration in the synovium, 
it remains to be determined when and which cell types 
infiltrate the synovium during the development of RA.
Interestingly, besides changes in blood vessels, the 
most reported feature of the synovium from uninvolved 
knee joints from patients with RA is increased numbers 
of synoviocytes or synovial lining cell hyperplasia.42 
This could indicate early changes in the synovial fibro-
blasts prior to clear synovial inflammation by the influx 
of immune cells. Synovial fibroblasts were found to be 
activated as seen by the expression of HLA-DR in biop-
sies without cellular infiltration. Additionally, previously 
activated synovial fibroblasts produced more cytokines 
such as IL-6 on a second stimulation.43 This enhanced 
reaction on a first activation or proinflammatory 
memory lasted for multiple days and was accompanied 
by prolonged NF-KB signalling. Of interest to note is the 
altered expression of IL-13 in the blood of patients with 
both seropositive and seronegative arthralgia, as well as 
IL-4 expression in patients with seropositive arthralgia. 
Both IL-13 and IL-4 are increased in synovial fluid from 
patients with a symptom duration of less than 3 months 
who developed RA.44 This increase in IL-4 and IL-13 in 
synovial fluid was transient as it was not detected in syno-
vial fluid of patients with established RA. The effect of 
IL-4 and IL-13 however is important as it protects synovial 
apoptosis.45 This protection allows synovial fibroblasts 
to survive NO generated by, for example, neutrophils. 
Protection against apoptosis can subsequently result in 
synovial hyperplasia and increased production of proin-
flammatory cytokines, RANKL expression and tissue 
damage by MMPs secretion. These findings indicate that 
synovial fibroblasts might play a role in the earliest phases 
of RA development and warrant additional research on 
these cells.
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ConCluSIonS And fuTure dIreCTIonS
In this review we build a model for RA pathogenesis for 
both seropositive and seronegative patients (see figure 1). 
We focused on data obtained from studies reporting 
on patients with arthralgia, pre-RA and recently diag-
nosed RA. Most of the reviewed studies on patients with 
arthralgia were cross-sectional in design, which leads 
to information about that specific time point within 
RA development. Due to the study design it is often 
unknown who of the patients with arthralgia developed 
RA and how much time there is between the presented 
data and the actual RA diagnosis. Therefore most of the 
obtained results are hard to place on a timeline of RA 
development. An example is the contradicting data on 
cellular influx of the synovium. Additionally, due to the 
limited number of studies on patients with arthralgia, 
most changes have been reported only once. Confirming 
these immunological changes is important to determine 
if these alterations truly occur during RA development 
and whether they are pathological and a cause rather 
than consequence.
Future studies should include a large follow-up 
study with repetitive blood drawings for inflammatory 
measures, biopsies, as well as pain and bone measure-
ments to fully map changes over time in inflammation 
and bones. The focus should be on altered cell number 
or frequency and include changes in cell functionality. 
This will lead to a better understanding of RA develop-
ment instead of extending data from mechanistic in vitro 
studies towards earlier prediagnosis phases. Additionally 
there is a lack of information regarding patients with 
ACPA-negative arthralgia and ACPA-negative RA. The 
limited data so far do indicate differences in cytokines 
and chemokines, as well as immune cells, besides the 
presence or absence of autoantibodies between patients 
with seronegative and seropositive RA. Patients with 
seronegative arthralgia should therefore be included in 
follow-up studies as described above and followed until 
the diagnosis of RA is set.
Furthermore, studies directed to limit or prevent RA 
development via medication should take notion of differ-
ences in cytokines, chemokines and immune cell alter-
ations between patients with arthralgia and patients with 
recently diagnosed RA. These differences are a starting 
point to prevent, for example, the rise of cytokines or 
chemokines, or more ideally revert immune cell function 
and number to normal. Overall, the current knowledge 
of how RA develops in patients with seropositive as well as 
seronegative arthralgia is still slim. Large follow-up studies 
are needed to provide new insights into RA development.
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